Results 1 to 10 of about 35,624 (244)

In-house chromogenic anti-factor Xa assay: development, validation, and identification of factors predicting APTT discordance [PDF]

Frontiers in Medicine
BackgroundActivated partial thromboplastin time (APTT) is the conventional test for monitoring unfractionated heparin (UFH) therapy, but discordance with anti-factor Xa results frequently occurs in clinical practice, potentially leading to suboptimal ...
Lin Sun, Jinxia Zhao, Guohong Jiang, Wenfei Lu, Hui Rong, Limin Lun, Yuehan Wang, Tianhui Zhou   +7 more
doaj   +2 more sources

Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors [PDF]

Nature Communications, 2017
A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef, Koen M. Visscher, C. Ruben Vosmeer, Ka Lei Cheung, Pieter H. Reitsma, Daan P. Geerke, Mettine H. A. Bos   +6 more
doaj   +5 more sources

Monitoring anti-factor Xa activity in patients with chronic thromboembolic pulmonary hypertension treated with factor Xa inhibitors [PDF]

Scientific Reports
Direct oral anticoagulants (DOACs) have been used clinically in patients with chronic thromboembolic pulmonary hypertension (CTEPH) for secondary prevention after acute venous thromboembolism, although the data are limited.
Yoshihisa Nakano, Shiro Adachi, Miku Hirose, Takeshi Adachi, Itsumure Nishiyama, Kenichiro Yasuda, Masahiro Yoshida, Takahisa Kondo, Toyoaki Murohara   +8 more
doaj   +2 more sources

Direct factor Xa inhibitors and the risk of cancer and cancer mortality: A Danish population-based cohort study. [PDF]

PLoS Medicine
BackgroundPreclinical animal studies have suggested that myeloid cell-synthesized coagulation factor X dampens antitumor immunity and that rivaroxaban, a direct factor Xa inhibitor, can be used to promote tumor immunity. This study was aimed at assessing
Floris Bosch, Erzsébet Horváth-Puhó, Suzanne C Cannegieter, Nick van Es, Henrik T Sørensen   +4 more
doaj   +2 more sources

Non-vitamin K oral antagonist failure and tailored treatment in patients with atrial fibrillation and stroke [PDF]

Precision and Future Medicine, 2020
In case of any embolic event, treatment strategy should be established according to the pathomechanisms of failure of non-vitamin K oral anticoagulants (NOAC). A 72-year-old man was referred to our hospital with a sudden speech disturbance.
Hyung Jun Kim, Soyoun Choi, Hee-Jin Kim, Oh Young Bang   +3 more
doaj   +1 more source

Direct oral anticoagulant: Review article

Journal of Family Medicine and Primary Care, 2022
Venous thromboembolism (VTE) and atrial fibrillation (AF) is a major burden on the health care system. The average occurrence of venous thromboembolism annually is around 108 per 100,000 person-year.
Abdulrahman Nasiri, Ahmed AlQahtani, Nora H Rayes, Rawan AlQahtani, Reem Alkharras, Hamad Alghethber   +5 more
doaj   +1 more source

Factor Xa inhibitor for venous thromboembolism management in patient with cancer: a systematic review and meta-analysis [version 1; peer review: 2 approved]

F1000Research, 2021
Background: An earlier systematic review reported no differences in the incidence of recurrent venous thromboembolism and major bleeding between factor Xa inhibitors and standard anticoagulation.
Ardyan Wardhana, Johanes Nugroho Eko Putranto, Pirhot Lambok Marnala Yosua Siahaan, Yoga Alfian Noor, Makhyan Jibril Al Farabi   +4 more
doaj   +1 more source

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study

Frontiers in Medicine, 2022
BackgroundAnti-factor Xa activity has been suggested as a surrogate parameter for judging the effectiveness of pharmacological thromboprophylaxis with low molecular weight heparins in critically ill patients.
Christoph Dibiasi, Christoph Dibiasi, Johannes Gratz, Marion Wiegele, Andreas Baierl, Eva Schaden, Eva Schaden   +6 more
doaj   +1 more source

The Potential Role of Coagulation Factor Xa in the Pathophysiology of COVID-19: A Role for Anticoagulants as Multimodal Therapeutic Agents

TH Open, 2020
SARS-CoV-2 infection (COVID-19) results in local and systemic activation of inflammation and coagulation. In this review article, we will discuss the potential role of coagulation factor Xa (FXa) in the pathophysiology of COVID-19. FXa, a serine protease,
Galit H. Frydman, Michael B. Streiff, Jean M. Connors, Gregory Piazza   +3 more
doaj   +1 more source

Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland

Swiss Medical Weekly, 2023
Anticoagulants are essential in preventing and treating thrombosis. Unfortunately, their use is accompanied by an enhanced risk of bleeding. Since the introduction of direct oral anticoagulants (DOACs), the risk of major bleeding has been reduced but ...
Anne Angelillo-Scherrer, Alessandro Casini, Jan-Dirk Studt, Bernhard Gerber, Lorenzo A. Alberio, Pierre Fontana   +5 more
doaj   +1 more source